Tirtha Chakraborty
Director Técnico/Científico/I+D en VOR BIOPHARMA INC. .
Fortuna: 304 696 $ al 30/04/2024
Cargos activos de Tirtha Chakraborty
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| VOR BIOPHARMA INC. | Director Técnico/Científico/I+D | 01/11/2020 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultor / Asesor | 24/07/2023 | - |
Historial de carrera de Tirtha Chakraborty
Antiguos cargos conocidos de Tirtha Chakraborty.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/10/2018 | 01/10/2019 |
| CRISPR THERAPEUTICS AG | Director/Miembro de la Junta | 01/01/2015 | 01/10/2018 |
| Corporate Officer/Principal | 01/01/2015 | 01/10/2018 |
Formación de Tirtha Chakraborty.
| Tata Institute of Fundamental Research | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Suiza | 2 |
| India | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| Empresas privadas | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Bolsa de valores
- Insiders
- Tirtha Chakraborty
- Experiencia
